Biolidics

Bringing Clarity to Cancer

Press Release – For immediate release

BIOLIDICS' CLEARCELL® FX1 SYSTEM OBTAINS APPROVAL IN CHINA

Singapore, 4 November 2019 – **Biolidics Limited ("Biolidics" or the "Company"),** a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce its fully automated medical device, ClearCell® FX1 System, has obtained the Class I registration from China National Medical Products Administration (中国国家药品监督管理局) ("NMPA", previously known as CFDA).

Using just a blood sample, Biolidics' ClearCell® FX1 System employs a novel patented technology to separate and enrich cancer cells from blood, allowing users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) or perform further analysis on cancer cells.

The analysis of CTCs, employing Biolidics' ClearCell® FX1 System, has been noted to be the most highly developed liquid biopsy technique, as the presence of CTCs is generally regarded as the fundamental prerequisite to metastasis and their enumeration offers potential for many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

With this approval, Biolidics can now directly market and sell the ClearCell® FX1 System to hospitals, laboratories, research institutions and other medical institutions for in-vitro diagnostic ("IVD") testing, when combined together with other approved complementary downstream equipment and/or technology, throughout China.

According a report published in the latest Chinese Journal of Oncology (中华肿瘤杂志) in January 2019, there was an average number of over 10,000 Chinese people diagnosed with cancer per day in 2015.

It was also highlighted that China needs to spend more than RMB 220 billion annually on relevant medical services with the rising number of cancer patients.

With a strategic focus on China, Biolidics has entered into 4 collaborations, with Hunan Agen Medicine Laboratory Technology Co., Ltd., Zhongshan TopGene Medical Laboratory Co. Ltd., Genecast Biotechnology Co., Ltd. and Holistic Integrative Pharmacy Institute, Hangzhou Normal University for the development and commercialisation of laboratory-developed tests ("LDTs") in China, using the ClearCell® FX1 System and CTChip® FR1 biochips.

Notably, Hunan Agen Medicine Laboratory Technology Co., Ltd. has announced that it will start offering LDTs in China using Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip.

- END -

Biolidics

Bringing Clarity to Cancer

About Biolidics Limited
(Bloomberg Code: BLD: Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration.

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:

8PR asia

Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.